- Home
- TYRA vs BXC Comparison
TYRA vs BXC Comparison
Compare TYRA & BXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYRA
- BXC
- Stock Information
- Founded
- TYRA 2018
- BXC 2004
- Country
- TYRA United States
- BXC United States
- Employees
- TYRA N/A
- BXC 2000
- Industry
- TYRA Biotechnology: Pharmaceutical Preparations
- BXC Wholesale Distributors
- Sector
- TYRA Health Care
- BXC Consumer Discretionary
- Exchange
- TYRA Nasdaq
- BXC Nasdaq
- Market Cap
- TYRA 576.6M
- BXC 546.7M
- IPO Year
- TYRA 2021
- BXC 2004
- Fundamental
- Price
- TYRA $9.52
- BXC $63.37
- Analyst Decision
- TYRA Strong Buy
- BXC Strong Buy
- Analyst Count
- TYRA 7
- BXC 5
- Target Price
- TYRA $30.86
- BXC $115.40
- AVG Volume (30 Days)
- TYRA 298.0K
- BXC 82.7K
- Earning Date
- TYRA 05-08-2025
- BXC 07-29-2025
- Dividend Yield
- TYRA N/A
- BXC N/A
- EPS Growth
- TYRA N/A
- BXC N/A
- EPS
- TYRA N/A
- BXC 4.53
- Revenue
- TYRA N/A
- BXC $2,935,514,000.00
- Revenue This Year
- TYRA N/A
- BXC $3.40
- Revenue Next Year
- TYRA N/A
- BXC $5.01
- P/E Ratio
- TYRA N/A
- BXC $14.79
- Revenue Growth
- TYRA N/A
- BXC N/A
- 52 Week Low
- TYRA $6.42
- BXC $63.55
- 52 Week High
- TYRA $29.60
- BXC $134.79
- Technical
- Relative Strength Index (RSI)
- TYRA 45.60
- BXC 40.27
- Support Level
- TYRA $8.88
- BXC $64.91
- Resistance Level
- TYRA $9.68
- BXC $68.71
- Average True Range (ATR)
- TYRA 0.64
- BXC 2.12
- MACD
- TYRA -0.08
- BXC -0.07
- Stochastic Oscillator
- TYRA 26.98
- BXC 0.00
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
About BXC Bluelinx Holdings Inc.
BlueLinx Holdings Inc is engaged in the wholesale distribution of residential and commercial building products. Its business products are split into two categories: Structural products include items such as lumber, plywood, oriented strand board, rebar, and remesh and Specialty products include items such as engineered wood, siding, millwork, outdoor living, specialty lumber and panels, and industrial products. The company's operations are carried out throughout the United States.